Recently，Nantong Egens Biotechnology Co., LTD. applied for listing on the new OTC market. Notice shows Weijun Ou, the president of Egens, holding 35.07% shares and Weiguo Ou, board director of Egens, holding 9.04% shares. Both of them are holding 44.21% shares and actual control the company together.

Data shows, Egens’s revenue of 2013, 2014 and the first half of 2015 are ￥55.13 million, ￥88.85 million, ￥44.42 million; the net profit are ￥-734 thousand,￥-2.39 million and￥-2.94 million.

Notice shows the Egens revenue has increased sharply, but the investment of R&D and construction of sales team is increasing which made it doesn’t have profits.

Besides, the export income of Egens has a higher percentage of revenues, and it uses the dollar as the main currency. Because the exchange rate fluctuation is more frequently in recent years, the Egens will face the risk of exchange rate fluctuation.

Egens Biotechnology, a high-tech enterprise in Jiangsu, is a comprehensive biotechnology company combining biological material development, diagnostic reagent manufacturing and domestic and foreign trade. The company is located in Nantong Economic and Technology Development Zone, Jiangsu Provincial, China.